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More on probiotics
To the Editor: We hereby wish to correct some information
communicated about the product Lactéol Forte (capsule and
sachet) in the recently published article entitled ‘An evaluation
of nine probiotics available in South Africa, August 2003’.1
Elliott and Teversham1 tested nine products classified as
probiotics, to obtain the bacterial content per gram for the
indicated organisms and to determine the organisms present in
the products. Among the probiotic products, Lactéol Forte
(capsule and sachets) marketed in South Africa by Mirren Pty
Ltd was studied in order to check the label information
through taxonomic characterisation of recoverable bacterial
strains. 
Lactéol Forte is sold as a food supplement in South Africa,
but is not a probiotic. Our product does not, indeed, answer to
the definition given by the joint FAO/WHO Expert
Consultation on the Evaluation of Health and Nutritional
Properties of probiotics in food. From this definition, probiotic
products should contain live lactic acid bacteria which, when
consumed in adequate amounts as part of food, confer a health
benefit on the host. Lactéol Forte capsules and sachets are sold
as dietary supplements to be used as part of a prescribed diet
to assist in the normalisation of intestinal microbiological
imbalances.
We would like to point out that apart from South Africa, our
product is registered in France and in over 40 countries around
the world as a medicine used in the treatment of gastro-
intestinal diseases such as acute infectious diarrhoea. The
marketing authorisations obtained in those countries are
supported by pharmacological and clinical studies.2-13 Owing to
its pharmaceutical status, our product gives every guarantee in
terms of efficacy and safety. The quality of Lactéol Forte is
controlled during all the industrial processes according to the
French and European pharmaceutical regulations.
The specific characteristic of our product is that it consists of
heat-killed LB bacteria (Lactéol strain) and fermented culture
medium. The heat-killed LB bacteria from Lactobacillus genus
are traditionally classified as a Lactobacillus acidophilus based on
its biochemical characteristics. The Lactéol strain is derived
from original bacteria isolated in 1907 by Pierre Boucard. A
private reference deposit was made to the French Pasteur
Institute. The LB bacteria and fermented culture medium are
treated at 110°C for 60 minutes before freeze-drying. As
opposed to probiotics, the absence of viable bacteria is a
criterion of quality and safety. The heating of the microbial
bodies in fact ensures the stability of the high concentration of
bacteria (10 billion germs per sachet and 5 billion germs per
capsule) for its shelf life and a high level of safety (no risk of
translocation). This stabilisation by heating is possible as the
pharmacological properties of the Lactéol LB strain are heat
stable.
The microbial quality of each Lactéol Forte batch is
controlled in accordance with our registration file and the
European Pharmacopoeia. The other advantage of heat
treatment is to enhance the shelf life of our product in terms of
bacterial concentration in the finished product. The
concentration is determined by counting of bacterial bodies
using microscopy.
Clinical efficacy of Lactéol Forte
Lactéol Forte is widely used in the prevention and treatment of
gastro-intestinal disturbances of bacterial and viral origin.
Several clinical studies10-13 have proved its effectiveness in
reducing the duration of diarrhoea and stool frequency in
children and adults.
Pharmacological data
In vitro and animal pharmacological study expert reports
demonstrate four types of mechanisms: (i) direct bacteriostatic
activity due to chemical substances contained in L. acidophilus
LB; (ii) stimulation of growth of the defensive acidogenic flora;
(iii) nonspecific immunostimulation of mucosa; and (iv)
inhibition of adhesion to and invasion of human intestinal cells
by enterovirulent micro-organisms
As mentioned, the Lactéol LB strain retains its
pharmacological properties when it is stabilised by heating.3
We agree with the statement in the conclusion of the article
that ‘Certain health benefits of probiotics are strain specific’.
Strain definition of products should, indeed, be linked to
efficacy, eliminating the current extrapolation of data by some
manufacturers. Lactéol Forte is a specific product, containing L.
acidophilus (strain LB) and fermented culture medium. The
heat-killed bacteria ensure the stability of the product, while
the pharmacological properties are not altered. Therefore
Lactéol Forte cannot be compared with the probiotic products
mentioned in the article.
Elliott and Teversham1 discredited the quality and efficacy of
our product by subjecting it to evaluation methods that are not
applicable or appropriate.  We would appreciate either a
correction from the authors or confirmation of their results by
additional analysis performed on Lactéol Forte taking into
account the specific nature of our pharmaceutical product.
Gilles Chauvière
Axcan Pharma
Route de Bu
78550 Houdan
France
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To the Editor: I wish to comment on the paper by Elliot and
Teversham.1
As the marketing aspects of the paper and their
repercussions have been extensively covered in the South
African media, I shall concentrate on the scientific aspects only.
In particular, I would like to point out a number of
fundamental flaws and shortcomings of the paper that render
the conclusions presented highly questionable.
1. Methodology used in the evaluation
1.1 Determination of viable counts of probiotic bacteria
While determining the viable counts of probiotic bacteria,
particularly of bifidobacteria, which are strictly anaerobic
micro-organisms, it is essential to use: 
1.1.1 Special anaerobic diluents;
1.1.2  Anaerobic hoods in which the sampling of products,
preparation of dilutions and plating should take place;
1.1.3  Media plates with reducing compounds;
1.1.4  Special anaerobic incubators, with a strictly regulated
composition of gases, the ratios of which should be specified.
These conditions, the diluents, and the equipment listed
above were not specified, described or even mentioned in the
above paper.  The statement in the paper that the plates were
incubated ‘under anaerobic and microaerophilic conditions’ is
inadequate.  The conditions should have been specified
quantitatively. The difference in the oxygen concentration
between the ‘anaerobic and micro-aerophilic conditions’ was
crucial in this study.
The conditions under which the samples were removed from
the original containers, suspended, diluted and plated were
also of utmost importance, as even very low concentrations of
residual oxygen present during these procedures would lead to
the depletion of bifidobacteria.
It should be stressed, however, that low concentrations of
oxygen would not significantly affect the growth of
Lactobacillus reuteri and other lactobacilli, which being micro-
aerophilic can multiply in the presence of oxygen at low
concentrations.   
1.2 Problems with the counts in which no growth of micro-
organisms was detected
No information is given concerning the lowest dilutions from
which the triplicate aliquots were withdrawn to be plated on
the selective media. This aspect is of particular importance to
the products in which ‘0’ viable count was reported.  Unless
the lowest dilution from which the aliquots were plated is
specified and unless it represents the undiluted suspension,
such a statement is incorrect and misleading. Before a
conclusion that no living bacteria were detected can be
justified, it should be clearly stated how many undiluted
samples were tested.  
1.3. Culture media
1.3.1 The modified Columbia agar is a blood-containing
medium used for the cultivation of Brucella, Campylobacter,
Helicobacter, Corynebacterium, Streptococcus, Staphylococcus,
Gardnerella, etc. and is used in many different modifications.2
Therefore, a detailed description of its preparation is required
and should have been included in the paper.  This medium is
not generally used for the enumeration of bifidobacteria.2,3
The cultivation of bifidobacteria on this rather unusual
medium could have caused a lower recovery of these bacteria,
leading to false conclusions. 
1.3.2 Culture media for the identification of Enterococcus faecium
and Saccharomyces cerevisiae are not mentioned at all in the
article. As reliance on the identification of micro-organisms
based only and entirely on the electrophoretic patterns of the
DNA is not generally accepted, other criteria should have been
employed.   
1.4 DNA determinations
Not a single proof of the electrophoretic analysis of the DNA
originating from the investigated probiotic bacteria is
presented.  Likewise, no proof of the DNA analysis of the
control strains is provided.  For an example of how such a
study should be presented, please see Bevilacqua et al.4
As the conclusions of the authors relating to the species of
the probiotic bacterial strains investigated (and of the reported
yeast as well as enterococcal ‘infections’) rely only and entirely
on the DNA analysis, it was imperative to submit some kind of
proof.   The information that the reference strains originate
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from the database kept at the University of Ghent without
providing their designations (Culture Collection Numbers) is
inadequate.  
In addition, the extraction of DNA from lyophilised cultures
instead of using freshly harvested cultures is not generally
accepted.
2. Lack of statistical data   
Basic statistical data, an essential part of any study of this
nature, are not included in the paper.  The missing data are:
2.1 The number of samples of each product tested as well as
the number of capsules, tablets or sachets analysed for each
product are not mentioned.   It is essential to know whether the
results reported and the conclusions drawn were based on just
a single sample and a single analysis or on a greater number of
samples. For a reliable enumeration, 5 and not 3 aliquots are
customarily plated from each dilution on ‘surface plates’ or
suspended in liquid agar media for ‘poured plates’.
2.2  Data defining standard error and/or standard deviation.  It
is difficult to accept that the viable counts for all the analysed
samples for each individual product were identical.  Statistical
data reflecting the reliability and accuracy of any biological
determination cannot be omitted in a scientific publication. 
In addition, such elementary information as a batch number
of each product included in the study is missing.
3. Lack of controls
No control probiotic bacterial strains verifying the suitability of
the media chosen for the evaluation are reported.  In view of
the unconventional medium used for the recovery and
enumeration of Bifidobacterium, it was imperative to use a
control laboratory strain of Bifidobacterium and confirm the
viable count obtained.  
Similarly, controls confirming the reliability of the DNA
extraction method and of the determination of the
electrophoretic DNA patterns were not described.  As these
determinations constituted the only taxonomic criterion used,
this omission is significant. 
4. Current classification and identification of
bifidobacteria and lactobacilli
Since the publication of Leblond-Bourgey et al. in 19965 it has
been known that Bifidobacterium longum and B. infantis are
clustered together into cluster No. 6.  In view of the fact that
the SAMJ evaluation under discussion was based on genetic
analysis, it is not surprising that the electrophoretic patterns of
the DNA originating from B. longum and B. infantis were close
or identical.  Both names are currently used in the scientific
literature, both are correct and both can be used on product
labels.  
In the light of the above, the conclusion in the paper
regarding the ‘mislabelling’ of Combiforte product is incorrect.
For a reliable classification of bifidobacteria and lactobacilli,
the use of a number of independent methods, the
electrophoretic patterns being one of them, is recommended.4
In view of the purpose of this publication, more than one test
should have been included as ‘the taxonomic significance of
phenotypic characterisation of bifidobacteria cannot be
neglected’ (a recommendation in Bevilacqua et al.4 p. 184). 
5. Suitability of the DGGE method
The authors’ conclusion: ‘We believe that the DGGE
[denaturing gradient gel electrophoresis] method provides a
suitable standard for organism identification together with
standardised quantification’ is not substantiated.   It is not
based on the data presented as no comparison with other
methods of identification was provided in the paper.       
6. Contaminating micro-organisms
The authors reported the recovery of Saccharomyces cerevisae
from Lactovita capsules and Enterococcus faecium from
Culturelle sachets.  However, they omitted to state from which
dilution or at which concentration the contaminating micro-
organisms were isolated (in other words, how many colonies
were detected).   As it is possible  that a tested sample can be
contaminated during sampling, weighing or other
manipulations, their detection could have been purely
accidental. The authors of the article do not provide any
information regarding the degree of sterility during those
procedures.  
In view of the above, the statement relating to the presence
of contaminating organisms (in the case of Lactovita the only
recovered micro-organism) in these products should be
disregarded as being unsubstantiated. 
My concluding remarks
The paper makes an overall impression of being hurriedly
prepared, with flaws and omissions that cast serious doubt on
the results reported and conclusions drawn.  Some of the basic
prerequisites for a scientific paper of this nature, such as the
inclusion of controls, presentation of statistical data and a
detailed description of the methods used, are missing.  In an
evaluation of this nature the lack of batch numbers of the
products tested is unacceptable. 
In view of these very basic flaws and shortcomings of the
paper, as discussed above, it is my opinion that:
1. The paper should not have been accepted for publication
in a scientific journal.
2. The conclusions presented in the paper are
unsubstantiated.
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Taking into consideration the nature and purpose of this
publication, I would like to invite specialists in the field of
anaerobic bacteria and probiotic bacteria to evaluate my
remarks.  Should they confirm my comments and conclusions,
I would like to suggest that: 
1. The SAMJ should officially revoke the findings and
conclusions presented in the paper.
2. In view of the far-reaching consequences of the
conclusions published in the paper, the SAMJ should offer a
public apology to the parties affected, to be disseminated in the
media.
Ela Johannsen
Biaflora CC
45 Idol Road
Lynnwood Glen
Pretoria
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Knowing what you can take —
the ins and outs of drug-free sport
To the Editor: Last year Elana Meyer was suspended after
winning a 10 km road race when the caffeine level in her blood
was higher  than the acceptable level. Yet in 2004 caffeine has
been removed from the list of banned substances! Clearly the
field of drugs in sports is changing very rapidly.
For this reason the Discovery Health UCT/MRC Research
Unit of Exercise Science and Sports Medicine, in conjunction
with the Institute for Drug Free Sport, have put together an
informative workshop, which will serve to update everyone on
the current list of banned substances and procedures. The
workshop will include an overview of drugs in sport, a talk on
the latest issues and controversies on drugs in sport, and a
presentation on some facts and fallacies related to nutritional
aids that supposedly enhance sporting performance.
The speakers include Dr Shuaib Manjra, Director of the
South African Institute of Drug Free Sport, who will give an
overview of the different classes of banned substances and
procedures and explain the protocol for drug testing. Dr Ryan
Kohler will discuss the controversies in drug testing and drugs
in sport, and a registered dietician, Amanda Claassen, will
discuss an evidence-based approach to nutritional sporting
performance enhancers.
The workshop, sponsored by the Institute for Drug Free
Sport and supported by the SA Sports Medicine Association
(SASMA), will take place on 10 May 18h30 in the auditorium of
the Sports Science Institute of South Africa. To reserve your
place, please phone Pinky Bobo on (021) 650-4561. There will
be a R20 donation to the Ziphelele Mbambo Memorial fund,
but SASMA members and students can attend for free on
presentation of their registration cards.
K McQuaide
Sports Science Institute of South Africa
Newlands
Cape Town
Fee for service
To the Editor: Is it not interesting how the unaffordability-of-
medical-care debate in the press is led by big business players
and not by the patients or the doctors?
The villains of the piece are always the doctors and fee for
service. 
Is it not strange that in every other field of human
endeavour fee for service works, but not in medicine! Could it
be that the real problem lies with the third party payer? When I
see a patient and charge R100 he gives the third party R120 to
pay me — surely if we settled on R110 we would both be
happier?  Why do we need the intermediary?
The real beneficiaries in a managed care option are the third
parties and their shareholders. For both the patient and the
doctor the options become more and more restrictive.  Is this
not why the medical aid industry runs down fee for service
and promotes managed care?.
Necessities such as food, clothing and housing are provided
by private for profit markets. Or maybe food should also be
regulated by a manager with a list of what you may or may not
purchase. Food is certainly even more essential than medical
care, and certainly has a much bigger effect on the health of the
nation.
State interference in the market can only cause more
problems, as I see with the minimum benefits that must be
covered, some medical aids are only going to cover the benefit
100% if it is provided by a preferred provider! Hello! Who is
the preferred provider? Why, the state hospital. What an easy
way out for the medical aid industry!
Surely the best managers of the patients’ affairs are the
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